Patient retention, clinical outcomes and attrition-associated factors of HIV-infected patients enrolled in Zimbabwe's National Antiretroviral Therapy Programme, 2007-2010.
Identifieur interne : 000470 ( PubMed/Corpus ); précédent : 000469; suivant : 000471Patient retention, clinical outcomes and attrition-associated factors of HIV-infected patients enrolled in Zimbabwe's National Antiretroviral Therapy Programme, 2007-2010.
Auteurs : Tsitsi Mutasa-Apollo ; Ray W. Shiraishi ; Kudakwashe C. Takarinda ; Janet Dzangare ; Owen Mugurungi ; Joseph Murungu ; Abu Abdul-Quader ; Celia J I. WoodfillSource :
- PloS one [ 1932-6203 ] ; 2014.
English descriptors
- KwdEn :
- Adult, Anti-HIV Agents (therapeutic use), CD4 Lymphocyte Count, Female, HIV, HIV Infections (drug therapy), HIV Infections (psychology), HIV Infections (virology), Humans, Male, Medication Adherence (statistics & numerical data), Middle Aged, Patient Dropouts (statistics & numerical data), Proportional Hazards Models, Retrospective Studies, Risk Factors, Treatment Outcome, Zimbabwe.
- MESH :
- chemical , therapeutic use : Anti-HIV Agents.
- geographic : Zimbabwe.
- drug therapy : HIV Infections.
- psychology : HIV Infections.
- statistics & numerical data : Medication Adherence, Patient Dropouts.
- virology : HIV Infections.
- Adult, CD4 Lymphocyte Count, Female, HIV, Humans, Male, Middle Aged, Proportional Hazards Models, Retrospective Studies, Risk Factors, Treatment Outcome.
Abstract
Since establishment of Zimbabwe's National Antiretroviral Therapy (ART) Programme in 2004, ART provision has expanded from <5,000 to 369,431 adults by 2011. However, patient outcomes are unexplored.
DOI: 10.1371/journal.pone.0086305
PubMed: 24489714
Links to Exploration step
pubmed:24489714Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Patient retention, clinical outcomes and attrition-associated factors of HIV-infected patients enrolled in Zimbabwe's National Antiretroviral Therapy Programme, 2007-2010.</title><author><name sortKey="Mutasa Apollo, Tsitsi" sort="Mutasa Apollo, Tsitsi" uniqKey="Mutasa Apollo T" first="Tsitsi" last="Mutasa-Apollo">Tsitsi Mutasa-Apollo</name><affiliation><nlm:affiliation>AIDS and TB Department, Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe.</nlm:affiliation></affiliation></author><author><name sortKey="Shiraishi, Ray W" sort="Shiraishi, Ray W" uniqKey="Shiraishi R" first="Ray W" last="Shiraishi">Ray W. Shiraishi</name><affiliation><nlm:affiliation>Division of Global HIV/AIDS, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Takarinda, Kudakwashe C" sort="Takarinda, Kudakwashe C" uniqKey="Takarinda K" first="Kudakwashe C" last="Takarinda">Kudakwashe C. Takarinda</name><affiliation><nlm:affiliation>AIDS and TB Department, Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe.</nlm:affiliation></affiliation></author><author><name sortKey="Dzangare, Janet" sort="Dzangare, Janet" uniqKey="Dzangare J" first="Janet" last="Dzangare">Janet Dzangare</name><affiliation><nlm:affiliation>AIDS and TB Department, Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe.</nlm:affiliation></affiliation></author><author><name sortKey="Mugurungi, Owen" sort="Mugurungi, Owen" uniqKey="Mugurungi O" first="Owen" last="Mugurungi">Owen Mugurungi</name><affiliation><nlm:affiliation>AIDS and TB Department, Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe.</nlm:affiliation></affiliation></author><author><name sortKey="Murungu, Joseph" sort="Murungu, Joseph" uniqKey="Murungu J" first="Joseph" last="Murungu">Joseph Murungu</name><affiliation><nlm:affiliation>AIDS and TB Department, Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe.</nlm:affiliation></affiliation></author><author><name sortKey="Abdul Quader, Abu" sort="Abdul Quader, Abu" uniqKey="Abdul Quader A" first="Abu" last="Abdul-Quader">Abu Abdul-Quader</name><affiliation><nlm:affiliation>Division of Global HIV/AIDS, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Woodfill, Celia J I" sort="Woodfill, Celia J I" uniqKey="Woodfill C" first="Celia J I" last="Woodfill">Celia J I. Woodfill</name><affiliation><nlm:affiliation>Division of Global HIV/AIDS, Centers for Disease Control and Prevention (CDC), Accra, Ghana.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24489714</idno><idno type="pmid">24489714</idno><idno type="doi">10.1371/journal.pone.0086305</idno><idno type="wicri:Area/PubMed/Corpus">000470</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000470</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Patient retention, clinical outcomes and attrition-associated factors of HIV-infected patients enrolled in Zimbabwe's National Antiretroviral Therapy Programme, 2007-2010.</title><author><name sortKey="Mutasa Apollo, Tsitsi" sort="Mutasa Apollo, Tsitsi" uniqKey="Mutasa Apollo T" first="Tsitsi" last="Mutasa-Apollo">Tsitsi Mutasa-Apollo</name><affiliation><nlm:affiliation>AIDS and TB Department, Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe.</nlm:affiliation></affiliation></author><author><name sortKey="Shiraishi, Ray W" sort="Shiraishi, Ray W" uniqKey="Shiraishi R" first="Ray W" last="Shiraishi">Ray W. Shiraishi</name><affiliation><nlm:affiliation>Division of Global HIV/AIDS, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Takarinda, Kudakwashe C" sort="Takarinda, Kudakwashe C" uniqKey="Takarinda K" first="Kudakwashe C" last="Takarinda">Kudakwashe C. Takarinda</name><affiliation><nlm:affiliation>AIDS and TB Department, Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe.</nlm:affiliation></affiliation></author><author><name sortKey="Dzangare, Janet" sort="Dzangare, Janet" uniqKey="Dzangare J" first="Janet" last="Dzangare">Janet Dzangare</name><affiliation><nlm:affiliation>AIDS and TB Department, Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe.</nlm:affiliation></affiliation></author><author><name sortKey="Mugurungi, Owen" sort="Mugurungi, Owen" uniqKey="Mugurungi O" first="Owen" last="Mugurungi">Owen Mugurungi</name><affiliation><nlm:affiliation>AIDS and TB Department, Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe.</nlm:affiliation></affiliation></author><author><name sortKey="Murungu, Joseph" sort="Murungu, Joseph" uniqKey="Murungu J" first="Joseph" last="Murungu">Joseph Murungu</name><affiliation><nlm:affiliation>AIDS and TB Department, Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe.</nlm:affiliation></affiliation></author><author><name sortKey="Abdul Quader, Abu" sort="Abdul Quader, Abu" uniqKey="Abdul Quader A" first="Abu" last="Abdul-Quader">Abu Abdul-Quader</name><affiliation><nlm:affiliation>Division of Global HIV/AIDS, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Woodfill, Celia J I" sort="Woodfill, Celia J I" uniqKey="Woodfill C" first="Celia J I" last="Woodfill">Celia J I. Woodfill</name><affiliation><nlm:affiliation>Division of Global HIV/AIDS, Centers for Disease Control and Prevention (CDC), Accra, Ghana.</nlm:affiliation></affiliation></author></analytic><series><title level="j">PloS one</title><idno type="eISSN">1932-6203</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Anti-HIV Agents (therapeutic use)</term><term>CD4 Lymphocyte Count</term><term>Female</term><term>HIV</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (psychology)</term><term>HIV Infections (virology)</term><term>Humans</term><term>Male</term><term>Medication Adherence (statistics & numerical data)</term><term>Middle Aged</term><term>Patient Dropouts (statistics & numerical data)</term><term>Proportional Hazards Models</term><term>Retrospective Studies</term><term>Risk Factors</term><term>Treatment Outcome</term><term>Zimbabwe</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-HIV Agents</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Zimbabwe</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Medication Adherence</term><term>Patient Dropouts</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>CD4 Lymphocyte Count</term><term>Female</term><term>HIV</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Proportional Hazards Models</term><term>Retrospective Studies</term><term>Risk Factors</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Since establishment of Zimbabwe's National Antiretroviral Therapy (ART) Programme in 2004, ART provision has expanded from <5,000 to 369,431 adults by 2011. However, patient outcomes are unexplored.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24489714</PMID><DateCreated><Year>2014</Year><Month>02</Month><Day>03</Day></DateCreated><DateCompleted><Year>2014</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS ONE</ISOAbbreviation></Journal><ArticleTitle>Patient retention, clinical outcomes and attrition-associated factors of HIV-infected patients enrolled in Zimbabwe's National Antiretroviral Therapy Programme, 2007-2010.</ArticleTitle><Pagination><MedlinePgn>e86305</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0086305</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Since establishment of Zimbabwe's National Antiretroviral Therapy (ART) Programme in 2004, ART provision has expanded from <5,000 to 369,431 adults by 2011. However, patient outcomes are unexplored.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine improvement in health status, retention and factors associated with attrition among HIV-infected patients on ART.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective review of abstracted patient records of adults ≥ 15 years who initiated ART from 2007 to 2009 was done. Frequencies and medians were calculated for rates of retention in care and changes in key health status outcomes at 6, 12, 24 and 36 months respectively. Cox proportional hazards models were used to determine factors associated with attrition.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 3,919 patients, 64% were female, 86% were either WHO clinical stage III or IV. Rates of patient retention at 6, 12, 24 and 36 months were 90.7%, 78.1%, 68.8% and 64.4%, respectively. After ART initiation, median weight gains at 6, 12, and 24 months were 3, 4.5, and 5.0 kgs whilst median CD4+ cell count gains at 6, 12 and 24 months were 122, 157 and 279 cells/µL respectively. Factors associated with an increased risk of attrition included male gender (AHR 1.2; 95% CI, 1.1-1.4), baseline WHO stage IV (AHR 1.7; 95% CI, 1.1-2.6), lower baseline body weight (AHR 2.0; 95% CI, 1.4-2. 8) and accessing care from higher level healthcare facilities (AHR 3.5; 95% 1.1-11.2).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our findings with regard to retention as well as clinical and immunological improvements following uptake of ART, are similar to what has been found in other settings. Factors influencing attrition also mirror those found in other parts of sub-Saharan Africa. These findings suggest the need to strengthen earlier diagnosis and treatment to further improve treatment outcomes. Whilst decentralisation improves ART coverage it should be coupled with strategies aimed at improving patient retention.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mutasa-Apollo</LastName><ForeName>Tsitsi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>AIDS and TB Department, Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shiraishi</LastName><ForeName>Ray W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Division of Global HIV/AIDS, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takarinda</LastName><ForeName>Kudakwashe C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>AIDS and TB Department, Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dzangare</LastName><ForeName>Janet</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>AIDS and TB Department, Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mugurungi</LastName><ForeName>Owen</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>AIDS and TB Department, Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murungu</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>AIDS and TB Department, Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdul-Quader</LastName><ForeName>Abu</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Global HIV/AIDS, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woodfill</LastName><ForeName>Celia J I</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Division of Global HIV/AIDS, Centers for Disease Control and Prevention (CDC), Accra, Ghana.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>PEPFAR</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>01</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Int AIDS Soc. 2009 May 06;12:6</RefSource><PMID Version="1">19419543</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2005 Oct 1;40(2):219-25</RefSource><PMID Version="1">16186741</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J STD AIDS. 2009 Apr;20(4):221-4</RefSource><PMID Version="1">19304962</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Int AIDS Soc. 2011;14:52</RefSource><PMID Version="1">22050673</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2011 Jun 1;25(9):1189-97</RefSource><PMID Version="1">21505309</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2009 Oct 17;374(9698):1329</RefSource><PMID Version="1">19837252</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2010 Aug 7;376(9739):449-57</RefSource><PMID Version="1">20638120</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Med. 2006 Jul;3(7):e238</RefSource><PMID Version="1">16796402</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Public Health. 2007;7:63</RefSource><PMID Version="1">17459154</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2008 Mar 29;371(9618):1059-60</RefSource><PMID Version="1">18380032</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Opin HIV AIDS. 2010 Jan;5(1):18-26</RefSource><PMID Version="1">20046144</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Stat Med. 2009 Jul 10;28(15):1982-98</RefSource><PMID Version="1">19452569</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 2010 Jun;15 Suppl 1:1-15</RefSource><PMID Version="1">20586956</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 2010 Jun;15 Suppl 1:34-42</RefSource><PMID Version="1">20586958</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2004 Apr 15;38(8):1159-66</RefSource><PMID Version="1">15095223</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Clin Nutr. 2010 Apr;91(4):1138S-1142S</RefSource><PMID Version="1">20147470</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2008 Apr 23;22(7):873-82</RefSource><PMID Version="1">18427206</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr HIV/AIDS Rep. 2010 Nov;7(4):234-44</RefSource><PMID Version="1">20820972</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2010 Jan;24 Suppl 1:S5-15</RefSource><PMID Version="1">20023440</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2010 Aug 24;24(13):2041-50</RefSource><PMID Version="1">20613459</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 2007 Nov;12(11):1315-22</RefSource><PMID Version="1">17949401</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 2006 Aug 16;296(7):782-93</RefSource><PMID Version="1">16905784</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2010 Nov 27;376(9755):1838-45</RefSource><PMID Version="1">21071074</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2006 Mar 11;367(9513):817-24</RefSource><PMID Version="1">16530575</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2008 Oct 1;49(2):190-5</RefSource><PMID Version="1">18769349</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 2006 Aug 9;296(6):679-90</RefSource><PMID Version="1">16896111</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2007 Dec 1;196 Suppl 3:S464-8</RefSource><PMID Version="1">18181695</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2006 Dec 1;43(4):436-9</RefSource><PMID Version="1">17019367</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>S Afr Med J. 2008 Mar;98(3):204-8</RefSource><PMID Version="1">18350223</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 2010 Jun;15 Suppl 1:90-7</RefSource><PMID Version="1">20586966</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2008 Nov 12;22(17):2303-11</RefSource><PMID Version="1">18981769</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2013;8(2):e56088</RefSource><PMID Version="1">23418518</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 2013 May;18(5):619-31</RefSource><PMID Version="1">23419157</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2009;4(6):e5790</RefSource><PMID Version="1">19495419</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 2012 May;17(5):564-80</RefSource><PMID Version="1">22394050</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2011 Jul 1;57(3):e33-9</RefSource><PMID Version="1">21372723</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2011;6(4):e18453</RefSource><PMID Version="1">21483703</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Gen Intern Med. 2013 Jan;28(1):91-8</RefSource><PMID Version="1">22903407</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2010 Sep;55(1):1-7</RefSource><PMID Version="1">20622679</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):49-55</RefSource><PMID Version="1">19617847</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2009 Apr 27;23(7):853-61</RefSource><PMID Version="1">19287299</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2010;5(9):e12888</RefSource><PMID Version="1">20877631</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2009 Sep 1;49(5):787-98</RefSource><PMID Version="1">19624276</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 2010 Dec;15(12):1413-20</RefSource><PMID Version="1">20958897</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Opin HIV AIDS. 2010 Jan;5(1):70-7</RefSource><PMID Version="1">20046150</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Public Health. 2012;12:124</RefSource><PMID Version="1">22329930</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018791" MajorTopicYN="N">CD4 Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006678" MajorTopicYN="Y">HIV</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055118" MajorTopicYN="N">Medication Adherence</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010352" MajorTopicYN="N">Patient Dropouts</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015030" MajorTopicYN="N" Type="Geographic">Zimbabwe</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC3906052</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>06</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>12</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24489714</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0086305</ArticleId><ArticleId IdType="pii">PONE-D-13-26776</ArticleId><ArticleId IdType="pmc">PMC3906052</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000470 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000470 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:24489714
|texte= Patient retention, clinical outcomes and attrition-associated factors of HIV-infected patients enrolled in Zimbabwe's National Antiretroviral Therapy Programme, 2007-2010.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24489714" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SidaGhanaV1
| This area was generated with Dilib version V0.6.31. |  |